57IN - Next generation technology for next generation trials

Date 27 September 2014
Event ESMO 2014
Session Personalised medicine in head and neck cancer
Topics Head and Neck Cancers
Translational Research
Presenter Christophe Le Tourneau
Citation Annals of Oncology (2014) 25 (suppl_4): iv21-iv21. 10.1093/annonc/mdu302
Authors C. Le Tourneau, M. Kamal
  • Department Of Medical Oncology, Institut Curie, 75005 - Paris/FR

Abstract

Body

Abstract:

Cancer is assumed to be driven by a succession of genomic alterations. However, genomics has practically entered the clinic in oncology only with the emergence of molecularly targeted agents (MTAs). These agents are supposed to be able only in the presence of their target(s). Some MTAs have been approved with a companion diagnostic based on a specific genomic molecular alteration, while some others have been approved in specific tumor types, such as cetuximab that targets EGFR in head and neck squamous cell carcinoma. The occurrence of the same genomic alteration across various tumor types is well described, although the incidence and functional impact may vary. The latter raises the question of whether treatment decision in the future should be entirely based on molecular biology, independently of tumor location and histology. This approach can today be addressed in clinical trials, since major advances in high throughput technologies now make it possible to depict most druggable molecular alterations for an affordable cost in a time that is compatible with clinical practice. We will review some of these histology-independent personalized medicine trials and discuss what benefits can be expected for head and neck cancer patients to participate in these trials in the light of the latest next generation screening results in Head and Neck cancer. High throughput technologies have entered the clinic with the aim to improving patients outcomes.

Disclosure:

All authors have declared no conflicts of interest.